#HVO hVIVO PLC – Euronext cancellation August 5, 2024 – Posted in: hVIVO (HVO), Vela Technologies Plc (VELA)

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its intention to cancel its admission (“the Cancellation”) to trading on Euronext Growth. As hVIVO’s primary operations, along with the majority of its employees and investor base, are in the UK, the Board has decided to consolidate trading of the Company’s stock to its primary…

#HVO hVIVO PLC – Notice of Results March 27, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its full year results for the twelve months ended 31 December 2023 on Tuesday 9 April 2024. Analyst briefing A briefing open to equity research analysts will take place on Tuesday 9 April 2024 at 12.00 pm BST. To…

#VELA investee #CDT Conduit Pharmaceuticals – Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub March 13, 2024 – Posted in: Vela Technologies Plc (VELA)

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”) today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of a robust intellectual property portfolio. The laboratory…

#VELA investee co. #ENSI EnSilica PLC – Receipt of R&D tax credit February 29, 2024 – Posted in: Vela Technologies Plc (VELA)

Receipt of R&D tax credit The Company is pleased to advise that it has now received payment for the 2023 R&D tax credit that was referred to in the Company’s interims results on 26 February 2024. For further information please contact: EnSilica plc Ian Lankshear, Chief Executive Officer www.ensilica.com Via Vigo Consulting +44 (0)20 7390 0233 Allenby Capital Limited, Nominated Adviser & Broker Jeremy Porter / Vivek Bhardwaj (Corporate Finance) Joscelin Pinnington/Tony Quirke (Sales &…

#HVO hVIVO PLC – Long Term Incentive Plan / PDMR Notification February 15, 2024 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the Company has granted options to Stephen Pinkerton, Chief Financial Officer, under its Long Term Incentive Plan (“LTIP”). The LTIP has been designed to reward, incentivise and retain Mr Pinkerton to deliver sustainable growth for shareholders. Under the rules of the LTIP, the…

#POLB Poolbeg Pharma PLC – POLB 001 LPS Trial Data to be Presented at IUIS November 16, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology (‘IUIS’), to be held 27 November – 2 December 2023 in Cape Town, South Africa. IUIS is the world’s…

#HVO hVIVO PLC – Annual Report and Notice of AGM April 28, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2022 and the Notice of Annual General Meeting (“AGM”) will be posted to shareholders today. The 2022 Annual Report and Accounts, the Notice of AGM and accompanying form…

#HVO hVIVO PLC – Final results April 25, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited results for the 12 months ended 31 December 2022. Financial highlights · Revenue up 30% to £50.7m (2021: £39.0m) · EBITDA increased threefold to £9.1m (2021: £2.9m) · EBITDA margins of 17.9% (2021: 7.4%), ahead of guidance due…

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Cidara Therapeutics, Inc. (“Cidara”), reporting positive interim results from an ongoing human challenge study testing CD388. hVIVO is conducting the Phase 2a single-center, randomised, double-blinded, placebo-controlled trial using its H3N2 Influenza Human Challenge Study Model. CD388 is…

#HVO hVIVO Plc – Exercise of Options March 23, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that it has issued 7,716,964 new ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”), pursuant to the exercise of share options by a former employee of the Company. It is expected that the admission of the Ordinary…